---
title: Optical Coherence Tomography in Staging Patients With Upper Tract Urothelial Cancer
nct_id: NCT02108587
overall_status: WITHDRAWN
phase: NA
sponsor: Case Comprehensive Cancer Center
study_type: INTERVENTIONAL
primary_condition: Kidney/Urinary Cancer
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02108587.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02108587"
ct_last_update_post_date: 2016-10-20
last_seen_at: "2026-05-12T06:38:37.185Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Optical Coherence Tomography in Staging Patients With Upper Tract Urothelial Cancer

**Official Title:** Staging of Upper Tract Urothelial Cancer With Optical Coherence Tomography

**NCT ID:** [NCT02108587](https://clinicaltrials.gov/study/NCT02108587)

## Key Facts

- **Status:** WITHDRAWN
- **Why Stopped:** Funding unavailable
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 0
- **Lead Sponsor:** Case Comprehensive Cancer Center
- **Collaborators:** National Cancer Institute (NCI)
- **Conditions:** Kidney/Urinary Cancer
- **Start Date:** 2016-12
- **CT.gov Last Update:** 2016-10-20

## Brief Summary

This clinical trial studies how well optical coherence tomography works in staging patients with upper-tract urothelial carcinomas. Staging describes the severity of a person's cancer based on the size and/or extent (reach) of the original (primary) tumor and whether or not cancer has spread in the body. It also helps the doctor plan the appropriate treatment. Optical coherence tomography is a procedure that uses infrared light waves to give three-dimensional pictures of structures inside tissues and organs. The pictures are made by a computer linked to the light source. Optical coherence tomography may be effective in staging patients with upper-tract urothelial carcinomas.

## Detailed Description

PRIMARY OBJECTIVES:

I. To test the feasibility and imaging ability of optical coherence tomography (OCT) to stage upper-tract urothelial carcinomas (UTUC).

OUTLINE:

Patients undergo optical coherence tomography over 10-15 minutes.

After completion of study, patients are followed up at 3 months.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Patients must have radiographic evidence of upper tract urothelial cancer by computed tomography (CT), magnetic resonance imaging (MRI) or intravenous pyelogram (IVP) in order to undergo this procedure
* Patient who will undergo standard of care clinical staging for UTUC
* Patient ability to read and comprehend the informed consent document

Exclusion Criteria:

* Patient who has a contraindication to endoscopy
* Patient who is pregnant
```

## Arms

- **optical coherence tomography for diagnosis** (EXPERIMENTAL) — Patients undergo optical coherence tomography over 10-15 minutes.

## Interventions

- **optical coherence tomography** (DEVICE) — Undergo optical coherence tomography

## Primary Outcomes

- **Feasibility of optical coherence tomography (OCT) images in staging upper-tract urothelial carcinomas (UTUC)** _(time frame: Up to 3 months)_ — Feasibility defined as the ability to relate the features associated with cancerous tissues in pathohistological analysis to the features in OCT images

## Secondary Outcomes

- **Imaging Analysis** _(time frame: Up to 3 months)_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.whyStopped` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT02108587.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT02108587*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*